Cutting-Edge Technology Singulex is a pioneer in Single Molecule Counting technology, offering unmatched sensitivity in biomarker detection. This innovative approach opens up sales opportunities to healthcare institutions seeking advanced diagnostic solutions.

Expansion Partnerships Recent collaborations with Qiagen, Grifols, and Manchester University showcase Singulex's commitment to expanding its reach. These partnerships create avenues for joint sales efforts, leveraging each partner's network and expertise.

Financial Stability With a revenue range of $50-100M and secured funding of $50M, Singulex presents a stable financial foundation. This financial health instills confidence in potential clients looking to invest in long-term partnerships for diagnostic solutions.

Competitive Positioning Singulex's positioning among similar companies like QIAGEN and 10x Genomics indicates a strong foothold in the biotechnology research industry. Leveraging this competitive position can drive sales growth by showcasing Singulex's unique offerings.

Market Expansion Singulex's move to launch assays detecting infectious and inflammatory diseases, along with a planned point-of-care platform, signals readiness for market expansion. Sales teams can capitalize on these upcoming products to tap into new customer segments.